EMA/775900/2022

European Medicines Agency decision

P/0455/2022

of 28 October 2022

on the acceptance of a modification of an agreed paediatric investigation plan for atidarsagene autotemcel (Libmeldy), (EMEA-001765-PIP02-15-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0455/2022

of 28 October 2022

on the acceptance of a modification of an agreed paediatric investigation plan for atidarsagene autotemcel (Libmeldy), (EMEA-001765-PIP02-15-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0222/2016 issued on 12 August 2016, the decision P/0160/2017 issued on 30 June 2017 and the decision P/0212/2018 issued on 17 July 2018,

Having regard to the application submitted by Orchard Therapeutics (Netherlands) B.V. on 19 May 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 September 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for atidarsagene autotemcel (Libmeldy), dispersion for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Orchard Therapeutics (Netherlands) B.V., 200 Prins Bernhardplein, 1097 JB – Amsterdam, The Netherlands.

EMA/PDCO/566788/2022
Amsterdam, 9 September 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001765-PIP02-15-M04

Scope of the application

Active substance(s):

Atidarsagene autotemcel

Invented name:

Libmeldy

Condition(s):

Treatment of metachromatic leukodystrophy (MLD)

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Dispersion for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Orchard Therapeutics (Netherlands) B.V.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Orchard Therapeutics (Netherlands) B.V. submitted to the European Medicines Agency on 19 May 2022 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0222/2016 issued on 12 August 2016, the decision P/0160/2017 issued on 30 June 2017 and the decision P/0212/2018 issued on 17 July 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 11 July 2022.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition

Treatment of metachromatic leukodystrophy (MLD)

2.1.1. Indication(s) targeted by the PIP

Treatment of presymptomatic Late Infantile (LI), and presymptomatic or early symptomatic Early Juvenile (EJ) and Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Dispersion for infusion

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of a cryopreserved dispersion for infusion formulation
Non-clinical studies	**Study 2** Study in As2-/- mice transplanted with bone marrow Lin- transduced with arylsulfatase A (ARSA) LV (GSK3485860; the murine equivalent of GSK2696274), to investigate the potential toxicity and tumorigenicity of GSK2696274
Clinical studies	**Study 3** Open label, non-randomised, single centre, externally controlled trial to evaluate safety and efficacy of a single infusion of GSK2696274 in patients with Late Infantile (LI) and Early Juvenile (EJ) Metachromatic Leukodystrophy (MLD) **Study 4** Open label, non-randomised, externally controlled trial to evaluate safety and efficacy of a single infusion of GSK2696274 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)

Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2035
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of metachromatic leukodystrophy

Authorised indication(s):

- Libmeldy is indicated for the treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arysulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity:
  - in children with late infantile or early juvenile forms, without clinical manifestations of the disease;
  - in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.

Authorised pharmaceutical form(s):

Dispersion for infusion

Authorised route(s) of administration:

Intravenous use